Journal article
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group
Cancers, Vol.18(5), 740
02/25/2026
DOI: 10.3390/cancers18050740
PMID: 41827675
Abstract
Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells and a rapidly evolving treatment landscape. Bispecific antibodies targeting B-cell maturation antigens (BCMA) have emerged as promising therapeutic options for relapsed and/or refractory multiple myeloma (RRMM). Methods: This retrospective study evaluated the efficacy and safety of teclistamab, a BCMA-directed bispecific antibody, in patients with RRMM with renal impairment (RI) at baseline compared to those without. Conducted across seven academic centers, the study included 195 patients with RRMM, of whom 34 had baseline RI. Results: Performance status, previous lines of treatment, and prior BCMA exposure were identified as significant predictors of progression-free survival. Notably, patients with RI demonstrated overall response rates and toxicity profiles comparable to those without RI, although they required more packed red blood cell transfusions. No statistically significant differences were observed in adverse events, including cytokine release syndrome and infections. Conclusions: Overall, the findings support the efficacy and safety of teclistamab in patients with RRMM and RI, highlighting the need for prospective clinical trials to optimize the treatment strategies for this population.
Details
- Title: Subtitle
- A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group
- Creators
- Maha Hameed - Florida State UniversityAlma Habib - University of Kansas Medical CenterAbdullah Mohammad Khan - The Ohio State UniversityMehak Masood Laharwal - Allegheny Health NetworkPrerna Mewawalla - Allegheny Health NetworkMarshall McKenna - Rutgers, The State University of New JerseyYun Kyuong Ryu Tiger - Rutgers, The State University of New JerseyMansi Shah - Rutgers, The State University of New JerseyHira Shaikh - University of IowaChristopher Strouse - University of IowaKimberly Green - Medical University of South CarolinaJordan Snyder - University of Kansas Medical CenterZahra Mahmoudjafari - University of Kansas Medical CenterMuhammad Umair Mushtaq - University of Kansas Medical CenterNausheen AhmedAl-Ola Abdallah - University of Kansas Medical CenterShebli Atrash - Levine Cancer InstituteBarry Paul - Levine Cancer InstituteReed Friend - Levine Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.18(5), 740
- DOI
- 10.3390/cancers18050740
- PMID
- 41827675
- NLM abbreviation
- Cancers (Basel)
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Publisher
- MDPI
- Grant note
- U.S. Myeloma Innovations and Research Collaborative (USMIRC)
The authors gratefully acknowledge the support of the U.S. Myeloma Innovations and Research Collaborative (USMIRC) for its contributions to this work, including assistance with study design, critical review of the manuscript, and administrative coordination.
- Language
- English
- Date published
- 02/25/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985141988002771
Metrics
4 Record Views